Summary of ongoing clinical trials of immune therapies in patients with hepatocellulars carcinoma (HCC)
| Type of immunotherapy | Molecules | NCT number | Phase | Population | Estimated enrollment | Recruitment status |
|---|---|---|---|---|---|---|
| Anti-PD-1 | Pembrolizumab | NCT03062358 | III | Advanced HCC, pre-treated | 450 | Recruiting |
| Nivolumab | NCT02576509 | III | Advanced HCC, naive | 1720 | Active, not recruiting | |
| NCT03383458 | III | Resected HCC | 530 | Recruiting | ||
| Combinations | ||||||
| Anti-PD-1 + Anti CTLA-4 | Durvalumab + tremelimumab | NCT03298451 | III | Advanced HCC, naive | 1310 | Recruiting |
| Nivolumab + ipilumumab | NCT03510871 | II | Eligible for curative surgery | 40 | Not yet recruiting | |
| NCT03222076 | II | Resected HCC | 45 | Recruiting | ||
| Angiogenesis and ICI | Nivolumab + bevacizumab | NCT03382886 | I | Advanced HCC, pre-treated | 12 | Active, not recruiting |
| Nivolumab + lenvatinib | NCT03418922 | I | Advanced HCC, pre-treated and naive | 30 | Active, not recruiting | |
| Pembrolizumab + lenvatinib | NCT03713593 | III | Advanced HCC, naive | 750 | Recruiting | |
| Transarterial chemoembolization and ICI | Nivolumab | NCT03572582 | II | Intermediate stage HCC | 49 | Recruiting |
| Durvalumab + tremelimumab | NCT03638141 | II | Intermediate stage HCC | 30 | Recruiting | |
| Y90-Radioembolization and Anti-PD-1 | Nivolumab | NCT03033446 | II | Advanced HCC | 40 | Recruiting |
CTLA-4 Cytotoxic T lymphocyte-associated protein 4; ICI immune checkpoint inhibitors; PD-1 programmed cell death-1; PD-L1 Programmed death-ligand 1